Fig. 3From: Preliminary report of a novel formulation of clinical-grade, fully matured, tumor-associated peptide-loaded dendritic cells for cancer immunotherapyImmunophenotype of pulsed mDC. Cells were characterized using the indicated differentiation and activation markers by flow-cytometry. No statistically significant difference was noted in the percent of positive events for each CD antigen across tested antigens or subjects (all one-way ANOVA p > 0.05)Back to article page